Astrazeneca Share News (AZN)

AstraZeneca's Calquence shows longer survival rate for leukaemia form

(Alliance News) - AstraZeneca PLC on Thursday said Calquence, when used in combination with obinutuzumab, showed a longer-term survival rate in people with a form of leukaemia.

AstraZeneca antibody reduces risk of severe Covid-19 or death

(Alliance News) - AstraZeneca PLC on Wednesday said its Evusheld antibody reduces the risk of serious Covid-19 symptoms or death from the virus in vulnerable sufferers.

Strong T-cell response for blood cancer patients after vaccine; COVID breakthrough often serious for cancer patients

June 6 (Reuters) - The following is a summary of some recent studies on COVID-19 and cancer presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Berenberg stays at 'buy' for AstraZeneca after trial results for Enhertu against breast cancer

(Sharecast News) - Analysts at Berenberg reiterated their 'buy' recommendation with a 120.0p target price for shares of AstraZeneca following the release of the company's clinical trial results for its treatment against metastatic breast cancer.

LONDON MARKET CLOSE: FTSE 100 rallies 1%; pound up ahead of UK PM vote

(Alliance News) - Equities in London had a buoyant start to the week after a four-day break, with oil majors and miners leading the gainers amid optimism over easing Covid rules in China.

LONDON MARKET MIDDAY: Pound unfazed as UK PM faces no-confidence vote

(Alliance News) - Stock prices in London were higher at midday on Monday following the long holiday weekend in the UK, after an easing of virus lockdowns in China, while the pound appreciated ahead of a no-confidence vote in Westminster.

AstraZeneca sees breast cancer drug Enhertu improve median overall survival

(Alliance News) - AstraZeneca PLC on Saturday said its jointly developed breast cancer drug Enhertu showed improved overall survival in a phase III trial, while its leukaemia treatment Calquence showed a sustained survival benefit in another phase III trial.

AstraZeneca-Daiichi's Enhertu reports positive survival rate results

(Sharecast News) - A treatment for breast cancer developed by AstraZeneca and Daiichi Sankyo has been shown to double the progression-free survival rates of patients compared with chemotherapy, according to trial data released on the weekend at a conference.

New data sets stage for broader use of AstraZeneca breast cancer drug

LONDON, June 5 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy, according to data presented on Sunday.

Breakthrough infections may be less contagious; vaccine protection wanes faster in cancer patients

May 26 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

Breakthrough infections may be less contagious

French health body backs new COVID vaccine booster campaign for this autumn

PARIS, May 25 (Reuters) - France's Haute Autorite de Sante (HAS) health authority recommended preparing for a new vaccination campaign this autumn to give people aged 65 and older, and those with special health risks or conditions, access to a COVID-19 "booster" jab.

U.S. Task Force to consider routine kidney disease screening as new drugs available

May 23 (Reuters) - An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier.

Omicron breakthrough infections may spare young hearts; no need to delay mammogram after vaccination

May 23 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

Indian vaccine giant Serum plans African plant in global expansion

DAVOS, Switzerland May 23 (Reuters) - The Serum Institute of India (SII), the world's biggest vaccine maker, is considering setting up its first manufacturing plant in Africa as it looks to expand globally after its success in selling COVID-19 shots, its CEO told Reuters on Monday.

U.S. Task Force to consider routine kidney disease screening

May 23 (Reuters) - An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier.